entertainment -WSS

entertainment

author：knowledge 2025-09-28 02:30:09 - browse：8

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Erich Jarvis studies song birds to learn about human stuttering

focus

WSS

Brain 'hot spot' may explain why African Americans feel greater pain

Bring on the sabbaticals for nurses

CRISPR technology availability, affordability needs to be expanded

Did the public have the right to know Arthur Ashe had AIDS?

4th of July breaks record for highest global temperature ever measured

'Patient friction coefficient' can gauge a clinical trial's patient burden

focus

entertainment

entertainment

Heart attack and stroke risk calculators need revising

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Walensky prepares to leave CDC — and Congress — behind

Option Care buys Amedisys in $3.6 billion home care deal

How to save PrEP access — and even expand it

When is a doctor not a doctor? Try when patients address women doctors

Malaria cases in Florida and Texas: Here’s what you need to know

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Illumina, CRISPR, Regeneron

entertainment

Brain 'hot spot' may explain why African Americans feel greater pain

Readout Newsletter: Illumina, CRISPR, Regeneron

New case study details death in closely watched Alzhiemer's trial

Did the public have the right to know Arthur Ashe had AIDS?

Biotech investment managers search for lucrative opportunities

CRISPR technology availability, affordability needs to be expanded

hotspot

focus

explore

hotspot